Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Q4 2025 value amounting to $111.9 million.

  • Arrowhead Pharmaceuticals' Current Deferred Revenue changed N/A to $111.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $111.9 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2025, which is N/A changed from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $111.9 million for Q4 2025.
  • Arrowhead Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $150.9 million during Q2 2021, with a 5-year trough of $866000.0 in Q3 2023.
  • Its 4-year average for Current Deferred Revenue is $74.9 million, with a median of $84.3 million in 2022.
  • In the last 5 years, Arrowhead Pharmaceuticals' Current Deferred Revenue soared by 151109.13% in 2021 and then plummeted by 9933.41% in 2023.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $108.7 million in 2021, then plummeted by 39.0% to $66.3 million in 2022, then plummeted by 98.69% to $866000.0 in 2023, then skyrocketed by 12825.29% to $111.9 million in 2025.
  • Its last three reported values are $111.9 million in Q4 2025, $2.4 million for Q3 2025, and $23.0 million during Q2 2025.